Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Sosei Heptares
Deal Size : $8.5 million
Deal Type : Agreement
Sosei Heptares to Receive US$2.5 Million Milestone Payment from Formosa Pharmaceuticals
Details : First patient is dosed in a 370-patient in Phase 3 trial of APP13007 in the US. Sosei Heptares will receive undisclosed milestone payments based on progression of Activus' pipeline and royalties from the commercialization of certain products should they ...
Brand Name : APP13007
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 11, 2021
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Sosei Heptares
Deal Size : $8.5 million
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
